Exscientia (EXAI) Stock Forecast, Price Target & Predictions
EXAI Stock Forecast
Exscientia stock forecast is as follows: an average price target of $5.00 (represents a -0.60% downside from EXAI’s last price of $5.03) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.
EXAI Price Target
The average price target for Exscientia (EXAI) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential -0.60% downside from EXAI's last price of $5.03.
EXAI Analyst Ratings
According to 2 Wall Street analysts, Exscientia's rating consensus is 'Hold'. The analyst rating breakdown for EXAI stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Exscientia Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Peter Lawson | Barclays | $5.00 | $4.77 | 4.89% | -0.60% |
The latest Exscientia stock forecast, released on Aug 13, 2024 by Peter Lawson from Barclays, set a price target of $5.00, which represents a 4.89% increase from the stock price at the time of the forecast ($4.77), and a -0.60% decrease from EXAI last price ($5.03).
Exscientia Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $5.03 | $5.03 | $5.03 |
| Upside/Downside | -100.00% | -0.60% | -0.60% |
In the current month, the average price target of Exscientia stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Exscientia's last price of $5.03. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Barclays | Overweight | Equal-Weight | Downgrade |
| Aug 08, 2024 | Cowen & Co. | Buy | Hold | Downgrade |
| Jul 09, 2024 | Cowen & Co. | - | Buy | Initialise |
| Nov 16, 2022 | Barclays | Overweight | Overweight | Hold |
Exscientia's last stock rating was published by Barclays on Aug 13, 2024. The company Downgrade its EXAI rating from "Overweight" to "Equal-Weight".
Exscientia Financial Forecast
Exscientia Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $5.76M | $8.20M | $7.03M | $8.66M |
| Avg Forecast | $26.11M | $26.02M | $12.59M | $8.07M | $13.24M | $4.48M | $6.62M | $7.23M | $6.11M | $21.09M | $39.01M |
| High Forecast | $64.61M | $64.40M | $31.14M | $19.98M | $32.77M | $11.10M | $16.38M | $17.88M | $15.11M | $52.18M | $39.01M |
| Low Forecast | $6.54M | $6.52M | $3.15M | $2.02M | $3.32M | $1.12M | $1.66M | $1.81M | $1.53M | $5.28M | $39.01M |
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | 0.80% | 1.34% | 0.33% | 0.22% |
Exscientia's average Quarter revenue forecast for Jun 23 based on 0 analysts is $6.62M, with a low forecast of $1.66M, and a high forecast of $16.38M. EXAI's average Quarter revenue forecast represents a 14.94% increase compared to the company's last Quarter revenue of $5.76M (Mar 23).
Exscientia EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $-38.18M | $-46.70M | $-49.72M | $-52.41M |
| Avg Forecast | $-24.70M | $-24.62M | $-11.90M | $-7.64M | $-12.53M | $-4.24M | $-6.26M | $-6.83M | $-5.78M | $-19.95M | $-36.90M |
| High Forecast | $-6.19M | $-6.16M | $-2.98M | $-1.91M | $-3.14M | $-1.06M | $-1.57M | $-1.71M | $-1.45M | $-4.99M | $-36.90M |
| Low Forecast | $-61.12M | $-60.92M | $-29.46M | $-18.90M | $-31.00M | $-10.50M | $-15.50M | $-16.91M | $-14.30M | $-49.36M | $-36.90M |
| Surprise % | - | - | - | - | - | - | - | 5.59% | 8.08% | 2.49% | 1.42% |
undefined analysts predict EXAI's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Exscientia's previous annual EBITDA (undefined) of $NaN.
Exscientia Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | $-37.64M | $-47.10M | $-39.62M | $-34.78M |
| Avg Forecast | $-18.45M | $-21.13M | $-23.94M | $-37.79M | $-34.50M | $-42.02M | $-41.38M | $-42.12M | $-38.19M | $-33.51M | $-19.52M |
| High Forecast | $-471.29K | $-19.72M | $-611.37K | $-965.34K | $-29.01M | $-1.07M | $-1.06M | $-1.08M | $-975.53K | $-856.01K | $-19.52M |
| Low Forecast | $-53.82M | $-21.83M | $-69.82M | $-110.24M | $-39.98M | $-122.56M | $-120.70M | $-122.87M | $-111.40M | $-97.75M | $-19.52M |
| Surprise % | - | - | - | - | - | - | - | 0.89% | 1.23% | 1.18% | 1.78% |
Exscientia's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. EXAI's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Exscientia SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | $10.91M | $9.90M | $11.51M | $14.63M |
| Avg Forecast | $30.99M | $30.89M | $14.94M | $9.58M | $15.72M | $5.32M | $7.86M | $8.58M | $7.25M | $25.03M | $46.31M |
| High Forecast | $76.69M | $76.44M | $36.97M | $23.71M | $38.89M | $13.17M | $19.45M | $21.22M | $17.94M | $61.93M | $46.31M |
| Low Forecast | $7.76M | $7.74M | $3.74M | $2.40M | $3.94M | $1.33M | $1.97M | $2.15M | $1.82M | $6.27M | $46.31M |
| Surprise % | - | - | - | - | - | - | - | 1.27% | 1.37% | 0.46% | 0.32% |
Exscientia's average Quarter SG&A projection for Jun 23 is $7.86M, based on 0 Wall Street analysts, with a range of $1.97M to $19.45M. The forecast indicates a -27.98% fall compared to EXAI last annual SG&A of $10.91M (Mar 23).
Exscientia EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 2 | 1 | - | 1 | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | $-0.31 | $-0.38 | $-0.32 | $-0.29 |
| Avg Forecast | $-0.15 | $-0.17 | $-0.19 | $-0.30 | $-0.27 | $-0.33 | $-0.33 | $-0.33 | $-0.30 | $-0.26 | $-0.15 |
| High Forecast | $-0.00 | $-0.16 | $-0.00 | $-0.01 | $-0.23 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.15 |
| Low Forecast | $-0.43 | $-0.17 | $-0.55 | $-0.87 | $-0.32 | $-0.97 | $-0.95 | $-0.97 | $-0.88 | $-0.77 | $-0.15 |
| Surprise % | - | - | - | - | - | - | - | 0.93% | 1.26% | 1.21% | 1.87% |
According to undefined Wall Street analysts, Exscientia's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to EXAI previous annual EPS of $NaN (undefined).
Exscientia Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| UBX | Unity Bio | $1.44 | $80.00 | 5455.56% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.11 | $2.83 | 154.95% | Buy |
| LPTX | Leap Therapeutics | $2.74 | $5.50 | 100.73% | Buy |
| AVIR | Atea Pharmaceuticals | $3.87 | $6.88 | 77.78% | Hold |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| RXRX | Recursion Pharmaceuticals | $6.57 | $9.67 | 47.18% | Hold |
| ZURA | Zura Bio | $3.70 | $5.00 | 35.14% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| EXAI | Exscientia | $5.03 | $5.00 | -0.60% | Hold |
EXAI Forecast FAQ
Is Exscientia a good buy?
No, according to 2 Wall Street analysts, Exscientia (EXAI) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of EXAI's total ratings.
What is EXAI's price target?
Exscientia (EXAI) average price target is $5 with a range of $5 to $5, implying a -0.60% from its last price of $5.03. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Exscientia stock go up soon?
According to Wall Street analysts' prediction for EXAI stock, the company can go down by -0.60% (from the last price of $5.03 to the average price target of $5), down by -0.60% based on the highest stock price target, and down by -0.60% based on the lowest stock price target.
Can Exscientia stock reach $8?
EXAI's average twelve months analyst stock price target of $5 does not support the claim that Exscientia can reach $8 in the near future.
What are Exscientia's analysts' financial forecasts?
Exscientia's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $31.57M (high $78.13M, low $7.91M), average EBITDA is $-29.866M (high $-7.479M, low $-73.906M), average net income is $-160M (high $-32.214M, low $-406M), average SG&A $37.48M (high $92.74M, low $9.39M), and average EPS is $-1.264 (high $-0.254, low $-3.208). EXAI's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $72.79M (high $180.13M, low $18.23M), average EBITDA is $-68.858M (high $-17.243M, low $-170M), average net income is $-101M (high $-21.769M, low $-256M), average SG&A $86.41M (high $213.81M, low $21.64M), and average EPS is $-0.8 (high $-0.172, low $-2.02).
Did the EXAI's actual financial results beat the analysts' financial forecasts?
Based on Exscientia's last annual report (Dec 2022), the company's revenue was $32.9M, which missed the average analysts forecast of $66.2M by -50.31%. Apple's EBITDA was $-229M, beating the average prediction of $-62.627M by 266.30%. The company's net income was $-143M, beating the average estimation of $-91.231M by 56.96%. Apple's SG&A was $46.4M, missing the average forecast of $78.59M by -40.96%. Lastly, the company's EPS was $-1.17, beating the average prediction of $-0.721 by 62.18%. In terms of the last quarterly report (Mar 2023), Exscientia's revenue was $5.76M, missing the average analysts' forecast of $7.23M by -20.27%. The company's EBITDA was $-38.178M, beating the average prediction of $-6.835M by 458.59%. Exscientia's net income was $-37.643M, missing the average estimation of $-42.124M by -10.64%. The company's SG&A was $10.91M, beating the average forecast of $8.58M by 27.26%. Lastly, the company's EPS was $-0.31, missing the average prediction of $-0.333 by -6.84%